National INFECT-TT program invests 7 million in accelerated clinical product development for infectious diseasesIn May 2026, the national valorisation programme InFECT-TT, under the umbrella of the InFECT-NL, will officially launch, together with the Infectious Diseases Innovation Fund (IDIF). InFECT-NL supports the clinical development of vaccines and therapies against infectious diseases and strengthens the pandemic preparedness of the Netherlands.
Phase 3 trial shows a reduction in recurrent ischemic strokeResearchers at Amsterdam UMC, in collaboration with colleagues worldwide, have shown in a phase 3 clinical trial that a new blood-thinning medication, asundexian, reduces the risk of a new stroke by approximately 25%. Importantly, the drug did not cause an increase in severe bleeding, which is a known side effect of potent blood thinners.
